However, analysts at Leerink were critical of the latter, saying that there were no significant increases in free fatty acids whereas free fatty acids decreased by 7.5 percent with pooled groups of tirzepatide in the Phase III SURMOUNT-1 trial. The analysts were referring to trial data for Eli Lillys Zepbound, which demonstrated a mean weight loss of 21.1 percent over 36 weeks in its trials involving nondiabetic patients with obesity or overweight, making MariTides results roughly on par with Zepbound, despite the difficulty of cross-trial comparisons
Gastrointestinal side effects occurred but rarely reached severity levels requiring treatment discontinuation
Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: A narrative review
n , Change in body weight
The proportion of weight lost as fat versus lean mass may be less favorable without deliberate muscle preservation strategies
Of course, its not just YouTubers that are taking and enjoying PT-141 either